CN Patent

CN112843007A — 一种奥拉帕利片

Assigned to CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd · Expires 2021-05-28 · 5y expired

What this patent protects

本发明提供了一种奥拉帕利片剂，采用一定重量比例的共聚维酮和聚维酮K17作为基质聚合物，能增加奥拉帕利固体分散体的稳定性，降低固体分散体和其形成片剂的吸湿性，避免溶出度显著变化。

USPTO Abstract

本发明提供了一种奥拉帕利片剂，采用一定重量比例的共聚维酮和聚维酮K17作为基质聚合物，能增加奥拉帕利固体分散体的稳定性，降低固体分散体和其形成片剂的吸湿性，避免溶出度显著变化。

Drugs covered by this patent

Patent Metadata

Patent number
CN112843007A
Jurisdiction
CN
Classification
—
Expires
2021-05-28
Drug substance claim
No
Drug product claim
No
Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.